Published in:
Open Access
01-12-2019 | Hypertension | Research article
Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy
Authors:
Majid Malekmohammad, Gert Folkerts, Babak Sharif Kashani, Parisa Adimi Naghan, Zahra Habibi Dastenae, Batoul Khoundabi, Johan Garssen, Esmaeil Mortaz, Ian M. Adcock
Published in:
BMC Pulmonary Medicine
|
Issue 1/2019
Login to get access
Abstract
Background
Idiopathic pulmonary arterial hypertension (IPAH) is a fatal illness. Despite many improvements in the treatment of these patients, there is no unique prognostic variable available to track these patients. The aim of this study was to evaluate the association between fractional exhaled nitric oxide (FeNO) levels, as a noninvasive biomarker, with disease severity and treatment outcome.
Methods
Thirty-six patients (29 women and 7 men, mean age 38.4 ± 11.3 years) with IPAH referred to the outpatient’s clinic of Masih Daneshvari Hospital, Tehran, Iran, were enrolled into this pilot observational study. Echocardiography, six-minute walking test (6MWT), FeNO, brain natriuretic peptide (BNP) levels and the functional class of patients was assessed before patients started treatment. Assessments were repeated after three months. 30 healthy non-IPAH subjects were recruited as control subjects.
Results
There was no significant difference in FeNO levels at baseline between patients with IPAH and subjects in the control group. There was also no significant increase in FeNO levels during the three months of treatment and levels did not correlate with other disease measures. In contrast, other markers of disease severity were correlated with treatment effect over the three months.
Conclusion
FeNO levels are a poor non-invasive measure of IPAH severity and of treatment response in patients in this pilot study.